Amgen announced Monday that its earnings fell in the third quarter on charges from an ongoing restructuring effort, but the biotech drugmaker’s adjusted results still surpassed Wall Street.
Amgen announced Monday that its earnings fell in the third quarter on charges from an ongoing restructuring effort, but the biotech drugmaker’s adjusted results still surpassed Wall Street.